- Home
- NXC vs PRLD Comparison
NXC vs PRLD Comparison
Compare NXC & PRLD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NXC
- PRLD
- Stock Information
- Founded
- NXC 1992
- PRLD 2016
- Country
- NXC United States
- PRLD United States
- Employees
- NXC N/A
- PRLD N/A
- Industry
- NXC Investment Managers
- PRLD Medicinal Chemicals and Botanical Products
- Sector
- NXC Finance
- PRLD Health Care
- Exchange
- NXC Nasdaq
- PRLD Nasdaq
- Market Cap
- NXC 82.6M
- PRLD 73.7M
- IPO Year
- NXC N/A
- PRLD 2020
- Fundamental
- Price
- NXC $13.10
- PRLD $0.87
- Analyst Decision
- NXC
- PRLD Strong Buy
- Analyst Count
- NXC 0
- PRLD 2
- Target Price
- NXC N/A
- PRLD $4.50
- AVG Volume (30 Days)
- NXC 17.5K
- PRLD 200.4K
- Earning Date
- NXC 01-01-0001
- PRLD 03-04-2025
- Dividend Yield
- NXC 3.97%
- PRLD N/A
- EPS Growth
- NXC N/A
- PRLD N/A
- EPS
- NXC 0.19
- PRLD N/A
- Revenue
- NXC N/A
- PRLD $3,000,000.00
- Revenue This Year
- NXC N/A
- PRLD N/A
- Revenue Next Year
- NXC N/A
- PRLD N/A
- P/E Ratio
- NXC $70.47
- PRLD N/A
- Revenue Growth
- NXC N/A
- PRLD N/A
- 52 Week Low
- NXC $11.86
- PRLD $0.80
- 52 Week High
- NXC $13.70
- PRLD $6.80
- Technical
- Relative Strength Index (RSI)
- NXC 48.44
- PRLD 37.59
- Support Level
- NXC $13.00
- PRLD $0.87
- Resistance Level
- NXC $13.19
- PRLD $1.01
- Average True Range (ATR)
- NXC 0.09
- PRLD 0.08
- MACD
- NXC -0.00
- PRLD -0.02
- Stochastic Oscillator
- NXC 25.64
- PRLD 0.90
About NXC Nuveen California Select Tax-Free Income Portfolio
Nuveen CA Select Tax Free Income Port is a diversified closed-end management investment company. Its objective is to provide stable dividends exempt from both regular federal and California income taxes, consistent with the preservation of capital by investing primarily in municipal obligations.
About PRLD Prelude Therapeutics Incorporated
Prelude Therapeutics Incorp is a clinical-stage precision oncology company focused on discovering and developing small molecule therapies optimized to target the key driver mechanisms in cancers with high unmet needs. The company's pipeline includes four candidates currently in clinical development: PRT1419, a potent, selective inhibitor of MCL1; PRT2527, a potent and selective CDK9 inhibitor, PRT3645, a next-generation CDK4/6 inhibitor, and PRT3789 a first-in-class SMARCA2/BRM protein degrader.